14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Cardiovascular diseases (CVDs), including ischemic heart disease, stroke, and heart failure, are well-established late effects of therapy in survivors of childhood and young adult (< 40 years at diagnosis) cancers; less is known regarding CVD in long-term survivors of adult-onset (≥ 40 years) cancer.

          Methods

          A retrospective cohort study design was used to describe the magnitude of CVD risk in 36,232 ≥ 2-year survivors of adult-onset cancer compared with matched (age, sex, and residential ZIP code) noncancer controls (n = 73,545) within a large integrated managed care organization. Multivariable regression was used to examine the impact of cardiovascular risk factors (CVRFs; hypertension, diabetes, dyslipidemia) on long-term CVD risk in cancer survivors.

          Results

          Survivors of multiple myeloma (incidence rate ratio [IRR], 1.70; P < .01), carcinoma of the lung/bronchus (IRR, 1.58; P < .01), non-Hodgkin lymphoma (IRR, 1.41; P < .01), and breast cancer (IRR, 1.13; P < .01) had significantly higher CVD risk when compared with noncancer controls. Conversely, prostate cancer survivors had a lower CVD risk (IRR, 0.89; P < .01) compared with controls. Cancer survivors with two or more CVRFs had the highest risk of CVD when compared with noncancer controls with less than two CVRFs (IRR, 1.83 to 2.59; P < .01). Eight-year overall survival was significantly worse among cancer survivors who developed CVD (60%) when compared with cancer survivors without CVD (81%; P < .01).

          Conclusion

          The magnitude of subsequent CVD risk varies according to cancer subtype and by the presence of CVRFs. Overall survival in survivors who develop CVD is poor, emphasizing the need for targeted prevention strategies for individuals at highest risk of developing CVD.

          Related collections

          Author and article information

          Journal
          J Clin Oncol
          J. Clin. Oncol
          jco
          jco
          JCO
          Journal of Clinical Oncology
          American Society of Clinical Oncology
          0732-183X
          1527-7755
          1 April 2016
          1 February 2016
          1 February 2016
          : 34
          : 10
          : 1122-1130
          Affiliations
          [1]Saro H. Armenian, Canlan Sun, and Sumanta Kumar Pal, City of Hope Comprehensive Cancer Center, Duarte; Lanfang Xu and Chun Chao, Kaiser Permanente Southern California, Pasadena; Leonardo T. Farol, City of Hope-Kaiser Permanente, Los Angeles, CA; Bonnie Ky, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Pamela S. Douglas, Duke Clinical Research Institute, Duke University, Durham, NC; and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL.
          Author notes
          Corresponding author: Saro H. Armenian, DO, MPH, City of Hope Comprehensive Cancer Center, 1500 East Duarte Rd, Duarte, CA 91010-3000; e-mail: sarmenian@ 123456coh.org .
          Article
          PMC7357493 PMC7357493 7357493 640409
          10.1200/JCO.2015.64.0409
          7357493
          26834065
          2ff609be-bb1a-4ef2-ac72-74a85e42edd1
          © 2016 by American Society of Clinical Oncology
          History
          Page count
          Figures: 1, Tables: 4, Equations: 0, References: 39, Pages: 10
          Categories
          EPID8, Population and observational studies (SEER, WHI observational, etc.)
          Original Reports
          Epidemiology
          Custom metadata
          v1

          Comments

          Comment on this article